Tyrosine Phosphorylation of Mitochondrial Pyruvate Dehydrogenase Kinase 1 Is Important for Cancer Metabolism

Molecular Cell

Volumn 44, Issue 6, 2011, Pages 864-877

  Hitosugi, Taro ^a   Fan, Jun ^a   Chung, Tae Wook ^a   Lythgoe, Katherine ^a   Wang, Xu ^a   Xie, Jianxin ^b   Ge, Qingyuan ^b   Gu, Ting Lei ^b   Polakiewicz, Roberto D ^b   Roesel, Johannes L ^c   Chen, Georgia Z ^a   Boggon, Titus J ^d   Lonial, Sagar ^a   Fu, Haian ^a   Khuri, Fadlo R ^a   Kang, Sumin ^a   Chen, Jing ^a  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b CELL SIGNALING TECHNOLOGY   (United States)

^c NOVARTIS PHARMA AG   (Switzerland)

^d YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE TRIPHOSPHATE; FIBROBLAST GROWTH FACTOR RECEPTOR 1; MITOCHONDRIAL ENZYME; PYRUVATE DEHYDROGENASE; PYRUVATE DEHYDROGENASE COMPLEX; PYRUVATE DEHYDROGENASE KINASE; TYROSINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL; CANCER INHIBITION; CELL HYPOXIA; CELL PROLIFERATION; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME BINDING; EXTRACELLULAR MATRIX; FEMALE; GENE MUTATION; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; IN VITRO STUDY; INTRACELLULAR SPACE; MITOCHONDRION; MOUSE; NONHUMAN; OXIDATIVE PHOSPHORYLATION; PROTEIN PHOSPHORYLATION; TUMOR GROWTH; TUMOR XENOGRAFT;

ANIMALS; FEMALE; MICE; MICE, NUDE; MITOCHONDRIA; NEOPLASM TRANSPLANTATION; NEOPLASMS; PHOSPHORYLATION; PROTEIN-SERINE-THREONINE KINASES; TRANSPLANTATION, HETEROLOGOUS; TYROSINE;

EID: 84255162057     PISSN: 10972765     EISSN: 10974164     Source Type: Journal    
DOI: 10.1016/j.molcel.2011.10.015     Document Type: Article

References (26)

1. Bonnet S., Archer S.L., Allalunis-Turner J., Haromy A., Beaulieu C., Thompson R., Lee C.T., Lopaschuk G.D., Puttagunta L., Bonnet S., et al. A mitochondria-K+ channel axis is suppressed in cancer and its normalization promotes apoptosis and inhibits cancer growth. Cancer Cell 2007, 11:37-51.
2. Gu T.L., Goss V.L., Reeves C., Popova L., Nardone J., Macneill J., Walters D.K., Wang Y., Rush J., Comb M.J., et al. Phosphotyrosine profiling identifies the KG-1 cell line as a model for the study of FGFR1 fusions in acute myeloid leukemia. Blood 2006, 108:4202-4204.
3. Hiromasa Y., Fujisawa T., Aso Y., Roche T.E. Organization of the cores of the mammalian pyruvate dehydrogenase complex formed by E2 and E2 plus the E3-binding protein and their capacities to bind the E1 and E3 components. J. Biol. Chem. 2004, 279:6921-6933.
4. Hitosugi T., Kang S., Vander Heiden M.G., Chung T.W., Elf S., Lythgoe K., Dong S., Lonial S., Wang X., Chen G.Z., et al. Tyrosine phosphorylation inhibits PKM2 to promote the Warburg effect and tumor growth. Sci. Signal. 2009, 2:ra73.
5. Kang S., Dong S., Gu T.L., Guo A., Cohen M.S., Lonial S., Khoury H.J., Fabbro D., Gilliland D.G., Bergsagel P.L., et al. FGFR3 activates RSK2 to mediate hematopoietic transformation through tyrosine phosphorylation of RSK2 and activation of the MEK/ERK pathway. Cancer Cell 2007, 12:201-214.
6. Kato M., Li J., Chuang J.L., Chuang D.T. Distinct structural mechanisms for inhibition of pyruvate dehydrogenase kinase isoforms by AZD7545, dichloroacetate, and radicicol. Structure 2007, 15:992-1004.
7. Kim J.W., Dang C.V. Cancer's molecular sweet tooth and the Warburg effect. Cancer Res. 2006, 66:8927-8930.
8. Kim J.W., Tchernyshyov I., Semenza G.L., Dang C.V. HIF-1-mediated expression of pyruvate dehydrogenase kinase: a metabolic switch required for cellular adaptation to hypoxia. Cell Metab. 2006, 3:177-185.
9. Kim J.W., Gao P., Liu Y.C., Semenza G.L., Dang C.V. Hypoxia-inducible factor 1 and dysregulated c-Myc cooperatively induce vascular endothelial growth factor and metabolic switches hexokinase 2 and pyruvate dehydrogenase kinase 1. Mol. Cell. Biol. 2007, 27:7381-7393.
10. Kobrin M.S., Yamanaka Y., Friess H., Lopez M.E., Korc M. Aberrant expression of type I fibroblast growth factor receptor in human pancreatic adenocarcinomas. Cancer Res. 1993, 53:4741-4744.
11. Kroemer G., Pouyssegur J. Tumor cell metabolism: cancer's Achilles' heel. Cancer Cell 2008, 13:472-482.
12. Liu S.J., Baker J.C., Roche T.E. Binding of the pyruvate dehydrogenase kinase to recombinant constructs containing the inner lipoyl domain of the dihydrolipoyl acetyltransferase component. J. Biol. Chem. 1995, 270:793-800.
13. Luqmani Y.A., Graham M., Coombes R.C. Expression of basic fibroblast growth factor, FGFR1 and FGFR2 in normal and malignant human breast, and comparison with other normal tissues. Br. J. Cancer 1992, 66:273-280.
14. Marek L., Ware K.E., Fritzsche A., Hercule P., Helton W.R., Smith J.E., McDermott L.A., Coldren C.D., Nemenoff R.A., Merrick D.T., et al. Fibroblast growth factor (FGF) and FGF receptor-mediated autocrine signaling in non-small-cell lung cancer cells. Mol. Pharmacol. 2009, 75:196-207.
15. Morrison R.S., Yamaguchi F., Bruner J.M., Tang M., McKeehan W., Berger M.S. Fibroblast growth factor receptor gene expression and immunoreactivity are elevated in human glioblastoma multiforme. Cancer Res. 1994, 54:2794-2799.
16. Olsen C. An enzymatic fluorimetric micromethod for the determination of acetoacetate, -hydroxybutyrate, pyruvate and lactate. Clin. Chim. Acta 1971, 33:293-300.
17. Papandreou I., Cairns R.A., Fontana L., Lim A.L., Denko N.C. HIF-1 mediates adaptation to hypoxia by actively downregulating mitochondrial oxygen consumption. Cell Metab. 2006, 3:187-197.
18. Penault-Llorca F., Bertucci F., Adélaïde J., Parc P., Coulier F., Jacquemier J., Birnbaum D., deLapeyrière O. Expression of FGF and FGF receptor genes in human breast cancer. Int. J. Cancer 1995, 61:170-176.
19. Pezzato E., Battaglia V., Brunati A.M., Agostinelli E., Toninello A. Ca2+ -independent effects of spermine on pyruvate dehydrogenase complex activity in energized rat liver mitochondria incubated in the absence of exogenous Ca2+ and Mg2+. Amino Acids 2009, 36:449-456.
20. Read R.J. Pushing the boundaries of molecular replacement with maximum likelihood. Acta Crystallogr. D Biol. Crystallogr. 2001, 57:1373-1382.
21. Roche T.E., Baker J.C., Yan Y.H., Hiromasa Y., Gong X.M., Peng T., Dong J.C., Turkan A., Kasten S.A. Distinct regulatory properties of pyruvate dehydrogenase kinase and phosphatase isoforms. Prog. Nucleic Acid Res. Mol. Biol. 2001, 70:33-75.
22. She H., Yang Q., Shepherd K., Smith Y., Miller G., Testa C., Mao Z. Direct regulation of complex I by mitochondrial MEF2D is disrupted in a mouse model of Parkinson disease and in human patients. J. Clin. Invest. 2011, 121:930-940.
23. Vander Heiden M.G., Cantley L.C., Thompson C.B. Understanding the Warburg effect: the metabolic requirements of cell proliferation. Science 2009, 324:1029-1033.
24. Warburg O. On the origin of cancer cells. Science 1956, 123:309-314.
25. Xiao S., Nalabolu S.R., Aster J.C., Ma J., Abruzzo L., Jaffe E.S., Stone R., Weissman S.M., Hudson T.J., Fletcher J.A. FGFR1 is fused with a novel zinc-finger gene, ZNF198, in the t(8;13) leukaemia/lymphoma syndrome. Nat. Genet. 1998, 18:84-87.
26. Yi H., Leunissen J., Shi G., Gutekunst C., Hersch S. A novel procedure for pre-embedding double immunogold-silver labeling at the ultrastructural level. J. Histochem. Cytochem. 2001, 49:279-284.